Since 2007, the guideline development process within the World Health Organization (WHO) has
been overseen by the WHO Guidelines Review Committee (GRC), which follows internationally
recognized standards such as the GRADE (Grading of Recommendations Assessment, Development
and Evaluation) approach, to su...
The present guideline update aims to use the best available evidence on the treatment of drug-susceptible TB, as well as on interventions to ensure adequate patient care and support, in order to inform policy decisions made in these technical areas by national TB control programme managers, national poli...
The specific objectives were to evaluate the harms to benefits ratio of delamanid in combination with the currently recommended MDR-TB treatment regimen in children. Based on this evaluation, to develop recommendations on the use of delamanid as part of WHO-recommended longer MDR-TB treatment regimens, a...
The overall objective of the guidelines is to provide public health approach guidance on evidencebased practices for testing, treating and managing LTBI in individuals with the highest risk of progression to active disease. The guidelines are expected to provide the basis and rationale for the developmen...
The aim of this guidance is to provide the interim principles that should guide the use of delamanid in conjunction with WHO-recommended MDR-TB treatment. It also specifies the essential treatment and management conditions for use of this drug, in particular the patient's eligibility criteria and safety ...
WHO estimates that up to half a million new cases of multidrug-resistant tuberculosis (MDR-TB) occur worldwide, each year. Current treatment regimens for MDR-TB present many challenges: treatment lasts 20 months or more, requiring daily administration of drugs that are more toxic, less effective, and far...
